Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Feb 14;17(1):247-255.
doi: 10.1159/000536351. eCollection 2024 Jan-Dec.

Experience and Lessons Learned in the Treatment of Transforming Small Cell Neuroendocrine Carcinoma of the Prostate: A Case Report and Literature Review

Binbin Song  1   2 , Yan Luo  2 , Qing Li  2 , Hong Pan  2 , Dong Li  1   2
Affiliations
Case Reports

Experience and Lessons Learned in the Treatment of Transforming Small Cell Neuroendocrine Carcinoma of the Prostate: A Case Report and Literature Review

Binbin Song et al. Case Rep Oncol. .

Abstract

Introduction: Small cell neuroendocrine carcinoma of the prostate (SCNECP) is a rare and highly malignant tumor that commonly transforms into conventional prostate adenocarcinoma (CPAC). Most of SCNECP cases cannot be detected and diagnosed early, and SCNECP is often diagnosed when there is liver and lung metastasis. Therefore, the early detection of the process from CPAC to SCNECP is crucial.

Case report: We present a case of a 73-year-old man who was initially admitted to our hospital with metastatic CPAC. He was administered goserelin acetate 3.6 mg combined with bicalutamide tablets (50 mg) once daily for endocrine therapy and docetaxel (100 mg) combined with prednisone (5 mg) twice a day. After treatment, the prostate-specific antigen (PSA) level decreased significantly, but the CEA, CA199, and CA125 levels began to increase progressively after a short decline. However, no solid tumor recurrence was observed in multiple reexaminations. It was not until 9 months after the elevation of tumor markers that multiple metastatic lesions appeared in the liver, which finally confirmed the diagnosis of metastatic SCNECP. After chemotherapy with etoposide 360 mg combined with carboplatin 200 mg, the tumor size was significantly reduced, and tumor markers decreased. However, the remission time was only 3 months. The patient's liver metastases continued to grow, and CEA, CA199, and CA125 levels continued to increase.

Conclusion: During CPAC treatment, PSA levels continued to decrease, whereas CEA, CA199, and CA125 levels continued to increase. This suggests the possibility of the transformation of CPAC into SCNECP.

Keywords: CA125; CA199; CEA; Small cell carcinoma of the prostate.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1.
Fig. 1.
Positron emission tomography/CT showed multiple bone metastases of PC (a) and CT showed hepatic cysts in the liver (b), there were no metastases in the liver (c).
Fig. 2.
Fig. 2.
Trend graph of tumor markers.
Fig. 3.
Fig. 3.
IHC. a Syn positive [×400]. b Insulinoma-associated protein 1(INSM1) positive [×400]. c PSA negative [×400]. d NSE positive [×400].
Fig. 4.
Fig. 4.
a On April 13, 2023, CT showed no metastasis of hepatic cysts. b On June 13, 2023, after the continuous increase of CEA, CA199, and CA125 for 9 months, CT showed diffuse multiple metastases in the liver. c After 3 cycles of etoposide combined with carboplatin chemotherapy, CT reexamination on August 17, 2023, showed that liver metastases were significantly reduced. d Reexamination of CT on September 12, 2023, showed that the liver metastasis increased again and the disease progressed.
Fig. 5.
Fig. 5.
Timeline summarizing the main events of this case report.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Bell PD, Huber AR, Agostini-Vulaj D. Clinicopathologic features of metastatic small cell carcinoma of the prostate to the liver: a series of four cases. Diagn Pathol. 2021;16(1):35. - PMC - PubMed
    1. Kelly K, Balk SP. Reprogramming to resist. Science. 2017;355(6320):29–30. - PubMed
    1. Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, et al. . Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355(6320):78–83. - PMC - PubMed
    1. Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, et al. . Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Invest. 2019;129(10):4492–505. - PMC - PubMed
    1. Van Bos E, Dekuyper P, Gabriel C, Waterloos M, Van Baelen A, Huybrechts S, et al. . Small cell carcinoma of the prostate after low-dose-rate brachytherapy: a case report. J Med Case Rep. 2020;14(1):203. - PMC - PubMed

Publication types